Pipeline — registered trials by phase
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
— · Relapsed/Refractory Multiple Myeloma(MM) · Recruiting · est. 2028-02-20
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
— · Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer · Active Not Recruiting · est. 2027-12
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
— · Relapsed/Refractory Autoimmune Diseases · Recruiting · est. 2029-12-31
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
— · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM) · Recruiting · est. 2028-01-31
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
— · Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung · Active Not Recruiting · est. 2027-12
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Legend Biotech is lead sponsor; 5 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- S-82026-10-07Employee stock plan
- 6-K2026-09-25Report of foreign issuer
- 6-K2026-09-24Report of foreign issuer
- 6-K2026-09-15Report of foreign issuer
- 6-K2026-09-14Report of foreign issuer
- 6-K2026-08-18Report of foreign issuer
- 6-K2026-08-11Report of foreign issuer
- 6-K2026-08-06Report of foreign issuer
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 6-K2026-07-27Report of foreign issuer
- 6-K2026-07-15Report of foreign issuer
- 6-K2026-06-22Report of foreign issuer
- 424B52026-06-18Prospectus (offering)
- 424B52026-06-17Prospectus (offering)
- F-6EF2026-06-17F-6EF
- 6-K2026-06-15Report of foreign issuer
- 6-K2026-06-02Report of foreign issuer
- 6-K2026-06-01Report of foreign issuer
- 6-K2026-05-21Report of foreign issuer
- 6-K2026-05-12Report of foreign issuer
- 6-K2026-04-14Report of foreign issuer
- 20-F2026-03-10Annual report (foreign)
- 6-K2026-03-10Report of foreign issuer
- 6-K2026-02-06Report of foreign issuer
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- 6-K2026-01-23Report of foreign issuer
- 6-K2026-01-21Report of foreign issuer
- 6-K2026-01-14Report of foreign issuer
- 6-K2026-01-12Report of foreign issuer
- 6-K2025-12-08Report of foreign issuer
- 6-K2025-11-12Report of foreign issuer
- SCHEDULE 13G/A2025-11-05SCHEDULE 13G/A
- 6-K2025-11-03Report of foreign issuer
- 6-K2025-10-14Report of foreign issuer
- 6-K2025-10-14Report of foreign issuer
- 6-K2025-10-07Report of foreign issuer
- 6-K2025-08-18Report of foreign issuer
- 6-K2025-08-11Report of foreign issuer
- SCHEDULE 13G/A2025-08-06SCHEDULE 13G/A
- 6-K2025-07-16Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.